Latest News - Genentech

Friday, October 27, 2017 | Healthcare Trends, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

ECTRIMS: Genentech Data Signals Emphasis on Multiple Sclerosis Disease Progression, Disability

Data presented by Genentech at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) -- Americas Committee for Treatment and Research in Multiple Sclerosis (ACT…

Read the full story

Thursday, September 14, 2017 | Movement Disorders, Research and Publications, Genentech

17 New Genes Linked to Parkinson’s Disease

A new study has discovered 17 novel genetic variants associated with Parkinson’s disease, several of which are considered targets for intervention. Published in Nature Genetics, the genome-wide …

Read the full story

Wednesday, April 26, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab

New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 …

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story

Wednesday, January 04, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

Newly Published Phase 3 Data Boost Efficacy Profile of Ocrevus in Primary Progressive and Relapsing MS

As the FDA continues its review of the Biologics License Application (BLA) for Genentech’s Ocrevus (ocrelizumab), key phase 3 findings reviewing the agent’s safety and efficacy in relapsin…

Read the full story

Wednesday, December 21, 2016 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Genentech, Roche

FDA Extends Review of MS Agent Ocrevus to March 2017

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics License Application of Genentech’s investigational agent for the treatment of multiple sclero…

Read the full story